Bayer AG said its blood thinner Xarelto matched the standard therapy at preventing blood clots in patients with an irregular heartbeat, results that may determine its success in a market worth as much as $14 billion a year.
Xarelto was as effective as warfarin, with “comparable” safety and rates of bleeding versus the standard therapy, Leverkusen, Germany-based Bayer said in a statement yesterday.
Boehringer Ingelheim GmbH last month beat Bayer and its partner Johnson & Johnson to market with Pradaxa, the first replacement for warfarin, the standard treatment over the past half century for patients with potentially deadly blood clots. Pfizer Inc. and Bristol-Myers Squibb Co. are also working on a replacement for the older treatment. Yesterday’s results are the first comparison between Xarelto and warfarin.
The market for new blood thinners including Xarelto may surpass 10 billion euros ($14 billion) a year, and Xarelto sales may peak at more than 2 billion euros, Bayer Chief Executive Officer Marijn Dekkers estimated in a Bloomberg Television interview on Oct. 28.
Bayer and J&J will present full results of the trial, called Rocket-AF, at the American Heart Association conference on Nov. 15.
Monday, November 01, 2010
Clot Wars contd. - Bayer Blood Thinner Xarelto Matches Warfarin in Irregular-Heartbeat Trial - Bloomberg
via bloomberg.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment